Eton Pharmaceuticals (NASDAQ:ETON) Insider Sells $229,421.62 in Stock

Key Points

• Insider sale: David Krempa sold 4,166 Eton Pharmaceuticals shares for approximately $229,422 at an average price of $55.07, reducing his direct stake by 8.76% to 43,381 shares.
• Financial performance: Eton reported quarterly earnings of $0.43 per share, exceeding the $0.19 consensus estimate, while revenue of $37.59 million also surpassed expectations.
• Analyst outlook: The stock has a “Moderate Buy” consensus rating and an average price target of $67.50, compared with a trading price near $54.77.

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) insider David Krempa sold 4,166 shares of the company's stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $55.07, for a total transaction of $229,421.62. Following the sale, the insider directly owned 43,381 shares in the company, valued at $2,388,991.67. This trade represents a 8.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

David Krempa also recently made the following trade(s):

• On Monday, August 24th, David Krempa sold 25,000 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $65.07, for a total transaction of $1,626,750.00.

Eton Pharmaceuticals Price Performance

Shares of ETON traded down $0.85 during mid-day trading on Tuesday, reaching $54.77. 467,654 shares of the stock traded hands, compared to its average volume of 447,832. The firm has a fifty day moving average price of $55.19 and a 200 day moving average price of $39.32. The company has a market cap of $1.57 billion, a price-to-earnings ratio of 144.13 and a beta of 0.90. The company has a current ratio of 1.52, a quick ratio of 1.30 and a debt-to-equity ratio of 0.41. Eton Pharmaceuticals, Inc. has a 1 year low of $14.27 and a 1 year high of $66.37.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.19 by $0.24. The firm had revenue of $37.59 million for the quarter, compared to analysts' expectations of $27.11 million. Eton Pharmaceuticals had a net margin of 12.02% and a return on equity of 40.13%. As a group, equities research analysts predict that Eton Pharmaceuticals, Inc. will post 1.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ETON has been the topic of several recent analyst reports. B. Riley Financial reaffirmed a "buy" rating and issued a $70.00 price target (up from $40.00) on shares of Eton Pharmaceuticals in a report on Friday, August 14th. Weiss Ratings raised shares of Eton Pharmaceuticals from a "sell (d-)" rating to a "hold (c)" rating in a research note on Tuesday, September 22nd. Canaccord Genuity Group increased their price target on shares of Eton Pharmaceuticals from $60.00 to $68.00 and gave the stock a "buy" rating in a report on Friday, August 14th. Craig Hallum raised their price objective on shares of Eton Pharmaceuticals from $40.00 to $62.00 and gave the company a "buy" rating in a research report on Tuesday, July 28th. Finally, HC Wainwright lifted their price objective on shares of Eton Pharmaceuticals from $65.00 to $70.00 and gave the stock a "buy" rating in a report on Friday, August 14th. Four research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Eton Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $67.50.

Hedge Funds Weigh In On Eton Pharmaceuticals

A number of large investors have recently modified their holdings of ETON. BlackRock Inc. purchased a new stake in Eton Pharmaceuticals in the second quarter worth approximately $68,629,000. EcoR1 Capital LLC grew its position in Eton Pharmaceuticals by 7.0% during the first quarter. EcoR1 Capital LLC now owns 2,171,938 shares of the company's stock valued at $53,603,000 after acquiring an additional 141,394 shares during the last quarter. Nantahala Capital Management LLC purchased a new position in shares of Eton Pharmaceuticals during the second quarter worth approximately $42,569,426. Pillsbury Lake Capital LLC purchased a new position in shares of Eton Pharmaceuticals during the second quarter worth approximately $14,015,083. Finally, Panoramic Capital LLC bought a new stake in shares of Eton Pharmaceuticals in the 2nd quarter worth approximately $7,537,000. 27.86% of the stock is owned by hedge funds and other institutional investors.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, acquiring, and commercializing treatments for rare diseases and other underserved patient populations. The company's strategy includes advancing proprietary product candidates and obtaining rights to established medicines that can address unmet medical needs.

Eton's portfolio has included products such as Eprontia (topiramate) oral solution for certain seizure disorders and migraine prevention, Biorphen (phenylephrine hydrochloride) injection for the treatment of clinically important hypotension, and specialty medicines used in the management of rare metabolic and endocrine conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.